94 results about "Cold adapted" patented technology

Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25° C. (and immunogenic compositions comprising the same) is also provided.

The cold-adapted master strain A/Ann Arbor/6/60 7PI (H2N2) and progenitor wild type E2(3) viral strains have been deposited and their genomic sequences identified. Seven nucleotide differences were found between the sequences identified herein and the previously published sequences for cold-adapted A/Ann Arbor/6/60 genes. The cold-adapted live influenza virus of the present invention can be reasserted with a variety of epidemic wild type influenza viruses and used to produce vaccines to prophylactically and therapeutically treat influenza.

This invention relates to apparatus and methods of delivering various compositions including medicaments to a variety of targets. The invention includes a dose administrator (1) which may be used for intranasal delivery of compositions or medicaments, such as live virus vaccines, to both humans and animals. An axial collapse prevention element (2) to prevent excessive axial deflection of the dose administrator (1) or a dose-location coordinate indicator (3) to facilitate the delivery of a dose to the desired target location may be coupled to the dose administrator (1). An intranasal probe (4) having a force dissemination contact surface (7) may be responsive to a first end of the dose administrator (1). The dose may be delivered from a conformable dose sequestration element (10) through an aperture which penetrates the dose delivery aperture element (5) and the dose may be caused to stream by coupling a stream delivery element (6) to the dose delivery aperture element (5). The force application element (12) which acts upon the dose may be separated from the dose by a fluid dose propellent (13). While the invention may be used for numerous applications, it specifically addresses the difficulties of delivering cold-adapted live equine influenza viruses intranasally to equids.

The invention discloses a compound microbial agent, a water-soluble fertilizer containing the same and applications of the compound microbial agent and the water-soluble fertilizer. The compound microbial agent is a mixture of high organic matter yeast fermentation liquid and traditional Chinese medicine extraction waste liquid, wherein the high organic matter yeast fermentation liquid is produced through microbial fermentation and is rich in amino acid. A preparation method is simple, dispenses with aseptic conditions and is low in cost. The compound microbial agent is prepared through mixed inoculated fermentation by taking bacillus subtilis, saccharomycetes, a cold-adapted bacterium VT16 and a cold-adapted bacterium VT19 as a composite strain and utilizing the high organic matter liquid produced through fermentation and rich in amino acid and the traditional Chinese medicine extraction waste liquid as raw materials, is comprehensive in nutrients and can not only provide nutrient elements required by crop growth but also inhibit reproduction of harmful microbes. The compound microbial agent is then combined with nutrients N, P and K essential to crops, wherein the added nutrients can meet the requirements of plant growth and have high absorptivity and good absorption effects; the added microbes can conduce to inhibiting growth of plant pathogens, preventing continuous cropping diseases, promoting growth of crops and inducing plants to become resistant.

Chimeric respiratory syncytial virus (RSV) and vaccine compositions thereof are produced by introducing one or more heterologous gene(s) or gene segment(s) from one RSV subgroup or strain into a recipient RSV backround of a different subgroup or strain. The resulting chimeric RSV virus or subviral particle is infectious and attenuated, preferably by introduction of selected mutations specifying attenuated phenotypes into a chimeric genome or antigenome to yield, for example, temperature sensitive (ts) and/or cold adapted (ca) vaccine strains. Alternatively, chimeric RSV and vaccine compositions thereof incorporate other mutations specifying desired structural and/or phenotypic characteristics in an infectious chimeric RSV. Such chimeric RSV incorporate desired mutations specified by insertion, deletion, substitution or rearrangement of one or more selected nucleotide sequence(s), gene(s), or gene segment(s) in a chimeric RSV clone. This provides a method for development of novel vaccines against diverse RSV strains by using a common attenuated backbone as a vector to express protective antigens of heterologous strains. The immune system of an individual is stimulated to induce protection against natural RSV infection, preferably in a multivalent manner to achieve protection against multiple RSV strains and/or subgroups.

The present invention provides vaccine compositions of attenuated human rotavirus. More particularly, the attenuated human rotavirus is produced by cold passage and thus contains attenuating mutations which produce virus having a cold-adapted (ca) and temperature sensitive (ts) phenotype. The attenuated strains are used in methods for stimulating the immune system of an individual to induce protection against human rotavirus by administration of the ca attenuated rotavirus.

The invention relates to an Antarctic cold-adapted microbial extracellular polysaccharide capable of improving body immunity, and belongs to the technical field of medicaments and health-care food. The cold-adapted microbial extracellular polysaccharide is prepared by culturing, fermenting, separating and purifying Antarctic cold-adapted bacteria (Pseudoaltermonas sp.) S-5, the strain collection number of which is CGMCC NO.3433. The molecular weight of the polysaccharide is 39,7046Da, and the polysaccharide consists of mannose, dextrose and galactose in a molar ratio of 4.8: 50.9: 44.3. The prepared Antarctic cold-adapted microbial extracellular polysaccharide capable of improving the body immunity can promote the proliferation of in vitro spleen lymphocytes, enhance the activity of macrophages and improve the body immunity.

The invention discloses an LDL-T strain as an attenuated vaccine strain for avian infectious bronchitis and application thereof, which belong to the field of prevention and treatment of the avian infectious bronchitis. The attenuated live vaccine strain CGMCC No.12549 for the avian infectious bronchitis provided by the invention has good safety and immune protection, the immune protection rate reaches 80 percent or more, and the LDL-T strain has good protective efficacy on TW I type avian infectious bronchitis viruses, and can effectively protect chickens against the attack of the TW I type infectious bronchitis viruses with strong virulent; moreover, the LDL-T strain is safe for chickens and laying breeders, side reaction does not exist, and the safety is good. The cold-adapted attenuated vaccine strain disclosed by the invention can be applied to the preparation of single vaccines, mixed vaccines and the like for preventing and treating the avian infectious bronchitis viruses.

The invention relates to an application of cold-adapted protease MCP-01 for tenderizing meat, which belongs to the technical field of food biological technology. The present invention has the following technical schemes for tenderizing meat: (1) preparing cold-adapted protease MCP-01 to a cold-adapted protease MCP-01 solution with the concentration of 5 - 20 micrograms/ml; (2) washing the meat required to be tenderized, and immersing into the cold-adapted protease MCP-01 solution obtained in step (1), storing at the temperature of 0 - 8 DEG C for 18 - 30 hours. The protease is capable of specifically degrading collagen in connective tissue of meat under the temperature of 0 - 4 DEG C, which has good potential application in the process of tenderizing meat.

The present invention refers to a composition comprising a solution which in turn comprises an amino acidic chain gelatin polymer derived from natural sources of cold-adapted marine species, at a concentration from 1% to 20% (w/v), which optionally further comprises a polymerizing initiator such as a photoinitiator, and is chemically functionalized to become reactive to polymerization or crosslinking in presence of free radicals. This composition is especially useful for 3D printing, extrusion systems (additive fabrication), spray systems, casting, micro- and nano fibers fabrication systems (electrospinning, solution blow spinning) or microfluidics.

The invention relates to alginate lyase with cold-adapted characteristics and an application thereof. The alginate lyase is a novel alginate lyase AlgA5, and an amino acid sequence is as shown by SEQID NO.1. In the sequence, a section of F5-F8-Type C structural domain (Gglu160-Ggly220) is designed, and the combinational structural domain can form a section of stable three-level structure, therebyinfluencing the cold-adapted performance of the lyase. The identity between the amino acid sequence of the alginate lyase AlgA5 and the sequence of the existing alginate lyase reaches up to 75 percent. The alginate lyase AlgA5 provided byof the invention has the cold-adapted characteristics, an acting way is an endonuclease way, a main product of the degradation of the cold-adapted alginate lyaseis unsaturatedalginate disaccharide and unsaturated alginate trisaccharide. The alginate lyase provided byof the invention is high in yield, stable in performance and high in industrialized application potential.

The present invention provides nucleic acid and corresponding amino acid sequences of two isoforms of cold adapted trypsin-like activity protein, insolated from antarctic marine origin, preferably from antarctic krill (Euphausia superba) that can be used in a variety of industrial contexts and commercial purposes including laundry detergents, food processing, drugs and skin care products. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the cold adapted trypsin-like protein.

The invention discloses externally tangent type algin lyase VsAly7D and a recombinant strain and application thereof. The amino acid sequence of the externally tangent type algin lyase disclosed by the invention is as shown in SEQ ID No.6, and the nucleotide sequence of the coding amino acid sequence is as shown in SEQ ID No.5. The suitable reaction temperature of the externally tangent type alginlyase is 20-35 DEG C, and the externally tangent type algin lyase has high stability at 0-30 DEG C, so that the enzyme can effectively degrade substrate at low temperature and belongs to cold-adaptedalgin lyase; the externally tangent type algin lyase has degradation capacity on algin, polyG and polyM, a degradation manner is an externally tangent type, and a final degraded product is unsaturated monose and has NaCl dependence. The invention further constructs a recombinant carrier and recombinant strain containing externally tangent type algin lyase VsAly7D coded genes, and a favorable basecan be provided for industrialized application and production of biologic ethanol.

The invention relates to a deep-sea cold-adapted and salt-tolerant collagenase as well as an encoding gene myr02 and application of the same, belonging to the field of biotechnology. The nucleotide sequence of a deep-sea cold-adapted and salt-tolerant collagenase gene myr02 is as shown in SEQ ID NO.1, and the nucleotide sequence of the collagenase myr02 encoded by the collagenase gene myr02 is as shown in SEQ ID NO.12. The collagenase myr02 can be used for degrading insoluble I type collagens, also has a higher activity for soluble substrates such as gelatins and the like, and has better cold adaptability and salt tolerance.